Press Release

  • March 4, 2013 Creation of Calypso Biotech SA, a Merck-Serono spin-off company to focus on gastrointestinal immunological disorders
    Download .pdf
  • May 14, 2013: Calypso Biotech acquires rights to monoclonal antibody for the treatment of refractory celiac disease
    Download .pdf
  • January 9, 2014: Calypso Biotech SA appoints world-class scientific advisory board and independent director to support the development of its therapeutic antibodies in gastroenterology indications
    Download .pdf
  • March 31, 2017: Calypso Biotech SA licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharm

      Download .pdf